Beaudart, Charlotte, Reginster, Jean-Yves, Thiyagarajan, Jotheeswaran Amuthavalli, Bautmans, Ivan, Bauer, Jurgen, Burlet, Nansa, Cesari, Matteo, Cherubini, Antonio, Cooper, Cyrus, Cruz-Jentoft, Alfonso Jose, Dawson-Hughes, Bess, Fielding, Roger A., Harvey, Nicholas, Landi, Francesco, Laslop, Andrea, Maggi, Stefania, Montero-Errasquin, Beatriz, Maria Concepcion, Prieto Yerro, Rolland, Yves, Rizzoli, Rene, Visser, Marjolein and Bruyère, Olivier (2023) Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties. Aging Clinical and Experimental Research, 35 (8), 1581-1593. (doi:10.1007/s40520-023-02438-3).
Abstract
Patient perspectives are now widely recognized as a key element in the evaluation of health interventions. Therefore, the provision of specific and validated Patient Reported Outcome Measures that emphasize the lived experience of patients suffering from specific diseases is very important. In the field of sarcopenia, the only validated specific health-related quality of life (HRQoL) instrument available is the Sarcopenia Quality of Life questionnaire (SarQoL). This self-administrated HRQoL questionnaire, developed in 2015, consists of 55 items arranged into 22 questions and has currently been translated into 35 languages. Nineteen validation studies performed on SarQoL have consensually confirmed the capacity of SarQoL to detect difference in HRQoL between older people with and without sarcopenia, its reliability and its validity. Two further observational studies have also indicated its responsiveness to change. A short form SarQoL, including only 14 items has further been developed and validated to reduce the potential burden of administration. Research on the psychometric properties of SarQoL questionnaire is still encouraged as the responsiveness to change of SarQoL has not yet been measured in the context of interventional studies, as limited prospective data currently exist and as there is still not cut-off score to define a low HRQoL. In addition, SarQoL has mainly been used in community-dwelling older individuals with sarcopenia and would benefit to be studied in other types of populations. This review aims to provide to researchers, clinicians, regulators, pharmaceutical industries and other stakeholders a clear summary of comprehensive evidence on the SarQoL questionnaire published up to January 2023Query.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.